The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.7M data for 1.2M Compounds and 9.0K Targets. Of those, 1,244K data for 572K Compounds and 4.4K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

61 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CHEBI
Jagiellonian University Medical College
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.EBI
Jagiellonian University Medical College
Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat.EBI
Astrazeneca
Tactical Approaches to Interconverting GPCR Agonists and Antagonists.EBI
University of Minnesota
Design, synthesis and biological evaluation of multifunctional ligands targeting opioid and bradykinin 2 receptors.EBI
University of Arizona
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.EBI
Institute of Organic Synthesis
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.EBI
Universit£
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.EBI
Broad Institute of Mit and Harvard
From bradykinin B2 receptor antagonists to orally active and selective bradykinin B1 receptor antagonists.EBI
Laboratoires Fournier
Design and synthesis of novel sulfonamide-containing bradykinin hB(2) receptor antagonists. Synthesis and structure-relationships ofa,a-tetrahydropyranylglycine.EBI
Menarini Ricerche
Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists.EBI
National Institute of Neuroscienc
Bradykinin receptor antagonists containing N-substituted amino acids: in vitro and in vivo B(2) and B(1) receptor antagonist activity.EBI
Cortech
A new series of highly potent non-peptide bradykinin B2 receptor antagonists incorporating the 4-heteroarylquinoline framework. Improvement of aqueous solubility and new insights into species difference.EBI
Fujisawa Pharmaceutical
Discovery of the first non-peptide full agonists for the human bradykinin B(2) receptor incorporating 4-(2-picolyloxy)quinoline and 1-(2-picolyl)benzimidazole frameworks.EBI
Fujisawa Pharmaceutical
A new class of nonpeptide bradykinin B(2) receptor ligand, incorporating a 4-aminoquinoline framework. Identification of a key pharmacophore to determine species difference and agonist/antagonist profile.EBI
Fujisawa Pharmaceutical
Nonpeptide bradykinin B2 receptor antagonists: conversion of rodent-selective bradyzide analogues into potent, orally-active human bradykinin B2 receptor antagonists.EBI
Novartis Institute For Medical Sciences
Synthesis and characterization of bradykinin B(2) receptor agonists containing constrained dipeptide mimics.EBI
University of Montpellier
Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety.EBI
University of Montpellier
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation.EBI
Fujisawa Pharmaceutical
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety.EBI
Fujisawa Pharmaceutical
A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man.EBI
Fujisawa Pharmaceutical
Design of potent non-peptide competitive antagonists of the human bradykinin B2 receptor.EBI
Sterling Winthrop Pharmaceutical Research Division
Design of non-peptide CCK2 and NK1 peptidomimetics using 1-(2-nitrophenyl)thiosemicarbazide as a novel common scaffold.EBI
Novartis Institute For Medical Sciences
 
Ace inhibitors as a template for the design of bradykinin B2 receptor antagonistsEBI
TBA
 
Synthesis of non-peptide bradykinin B2 receptor antagonistsEBI
TBA
 
Structure activity relationships of non-peptide bradykinin B2 receptor antagonistsEBI
TBA
Spiroindolones, a potent compound class for the treatment of malaria.EBI
Swiss Tropical and Public Health Institute
A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.EBI
Università
Novel small molecule bradykinin B2 receptor antagonists.EBI
Jerini
 
Synthesis and biological activity of new bradykinin pseudopeptide B1 receptor agonists containing alkylic spacersEBI
TBA
Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity.EBI
Amgen
Development of orally bioavailable and CNS penetrant biphenylaminocyclopropane carboxamide bradykinin B1 receptor antagonists.EBI
Merck Research Laboratories
Cyclopropylamino acid amide as a pharmacophoric replacement for 2,3-diaminopyridine. Application to the design of novel bradykinin B1 receptor antagonists.EBI
TBA
2,3-diaminopyridine bradykinin B1 receptor antagonists.EBI
Merck Research Laboratories
Development of an efficient and selective radioligand for bradykinin B1 receptor occupancy studies.EBI
Merck Research Laboratories
Potent and orally bioavailable non-peptide antagonists at the human bradykinin B(1) receptor based on a 2-alkylamino-5-sulfamoylbenzamide core.EBI
TBA
Design and synthesis of novel pyrrolidine-containing bradykinin antagonists.EBI
Johnson & Johnson Pharmaceutical Research & Development
Synthesis and structure--activity relationships of aroylpyrrole alkylamide bradykinin (B2) antagonists.EBI
Johnson & Johnson Pharmaceutical Research and Development
Structure-based design of six novel classes of nonpeptide antagonists of the bradykinin B2 receptor.EBI
Roche Bioscience
A rational approach to the design and synthesis of a new bradykinin B(1) receptor antagonist.EBI
University of Montpellier
Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists.EBI
University of Montpellier
1-(2-Nitrophenyl)thiosemicarbazides: a novel class of potent, orally active non-peptide antagonist for the bradykinin B(2) receptor.EBI
Novartis Institute For Medical Sciences
Pharmaceutical significance of azepane based motifs for drug discovery: A critical review.EBI
Wuhan Institute of Technology
The design of non-peptide human bradykinin B2 receptor antagonists employing the benzodiazepine peptidomimetic scaffold.EBI
Novartis Institute For Medical Sciences
Cinnamamide: An insight into the pharmacological advances and structure-activity relationships.EBI
National Institute of Pharmaceutical Education and Research (NIPER)
Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.EBI
Merck Healthcare
Rational Design of Cell-Active Inhibitors of PARP10.EBI
Oregon Health and Science University
Synthesis and characterization of pseudopeptide bradykinin B2 receptor antagonists containing the 1,3,8-triazaspiro[4.5]decan-4-one ring system.EBI
Scios Nova
Identification and biological evaluation of thiazole-based inverse agonists of ROR?t.EBI
Phenex Pharmaceuticals
Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide], on hemorrhagic and ischemic stroke.BDB
Taisho Pharmaceutical
N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.BDB
Pudue Pharma Discovery Research
The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.BDB
Janssen Research Foundation
ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse.BDB
Abbott Laboratories
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.BDB
Sanofi Recherche